ID   OCI-My7
AC   CVCL_E333
SY   OCI-MY7; OCI-My 7; OCIMy7; OCIMY7
DR   BioSample; SAMN10989617
DR   cancercelllines; CVCL_E333
DR   Cell_Model_Passport; SIDM01379
DR   Cosmic; 2081402
DR   Cosmic; 2367266
DR   DepMap; ACH-000436
DR   Wikidata; Q54931790
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=1912582;
RX   PubMed=8138440;
RX   PubMed=10936422;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Population: Caucasian.
CC   Doubling time: 57 hours (PubMed=1912582).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.65%; Native American=0%; East Asian, North=2.7%; East Asian, South=1.34%; South Asian=7.94%; European, North=21.26%; European, South=64.1% (PubMed=30894373).
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 20
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   PubMed=1912582; DOI=10.1182/blood.V78.8.1996.1996;
RA   Hitzler J.K., Martinez-Valdez H., Bergsagel D.B., Minden M.D.,
RA   Messner H.A.;
RT   "Role of interleukin-6 in the proliferation of human multiple myeloma
RT   cell lines OCI-My 1 to 7 established from patients with advanced stage
RT   of the disease.";
RL   Blood 78:1996-2004(1991).
//
RX   PubMed=8138440; DOI=10.1016/0360-3016(94)90107-4;
RA   Gluck S., Van Dyk J., Messner H.A.;
RT   "Radiosensitivity of human clonogenic myeloma cells and normal bone
RT   marrow precursors: effect of different dose rates and fractionation.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 28:877-882(1994).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//